• Policy
• New dementia drug Leqembi’s approval imminent in Korea
• by Lee, Hye-Kyung May 14, 2024 05:48am

• Company
• AbbVie’s Aquipta becomes the first oral CGRP migraine drug
• by Son, Hyung-Min May 13, 2024 05:52am

• Company
• BeiGene reapplies for Tevimbra’s reimb in esophageal cancer
• by Eo, Yun-Ho May 13, 2024 05:52am

• Company
• MM drug Tecvayli can be prescribed in tertiary hospitals
• by Eo, Yun-Ho May 13, 2024 05:52am

• Company
• Pharma companies showcase their R&D achievements
• by Son, Hyung-Min May 13, 2024 05:52am

• Policy
• SGLT-2 monotherapy 'Suglat' set to withdraw from KOR
• by Lee, Tak-Sun May 13, 2024 05:51am

• Company
• Hanmi’s 2 new accounts of the pipeline enter clinical trial
• by Son, Hyung-Min May 13, 2024 05:51am

• Company
• HSF therapy 'Altuviiio' receives Orphan Drug designation
• by Eo, Yun-Ho May 10, 2024 04:33pm

• Policy
• 'BIO KOREA 2024' begins
• by Lee, Hye-Kyung May 10, 2024 05:47am

• Opinion
• [Reporter’s View] The dark side of the coveted MNC jobs
• by Eo, Yun-Ho May 10, 2024 05:47am